Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mymd Pharmaceuticals Inc (MYMD)

4.86   0.14 (2.97%) 01-16 05:55
Open: 4.59 Pre. Close: 4.72
High: 4.98 Low: 4.59
Volume: 96,627 Market Cap: 183M
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.987 - 5.015 5.015 - 5.041
Low: 4.52 - 4.555 4.555 - 4.586
Close: 4.808 - 4.86 4.86 - 4.908

Technical analysis

as of: 2022-01-15 8:48:21 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 7.25     One year: 8.44
Support: Support1: 4.57    Support2: 3.80
Resistance: Resistance1: 6.21    Resistance2: 7.22
Pivot: 5.37
Moving Average: MA(5): 4.97     MA(20): 5.65
MA(100): 7.17     MA(250): 6.19
MACD: MACD(12,26): -0.52     Signal(9): -0.48
Stochastic oscillator: %K(14,3): 9.69     %D(3): 10.84
RSI: RSI(14): 33.33
52-week: High: 10.48  Low: 3.30  Change(%): -9.7
Average Vol(K): 3-Month: 15723  10-Days: 7495

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
MYMD has closed above bottom band by 17.2%. Bollinger Bands are 26.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 05 Jan 2022
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia - Business Wire

Wed, 29 Dec 2021
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia - Business Wire

Tue, 23 Nov 2021
MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan - Business Wire

Tue, 19 Oct 2021
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 - Business Wire

Tue, 05 Oct 2021
MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 - Business Wire

Wed, 22 Sep 2021
MyMD Pharmaceuticals Announces New Data Demonstrating 8000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD - Business Wire

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 38
Shares Float (M) 32
% Held by Insiders 8.12
% Held by Institutions 17.32
Shares Short (K) 926
Shares Short P. Month (K) 800

Stock Financials

EPS -0.810
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.690
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.744
Qtrly Earnings Growth
Operating Cash Flow (M) -16
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -6.00
PEG Ratio
Price to Book value 7.04
Price to Sales
Price to Cash Flow -11.56

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date 2019-11-24
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.